摘要
尽管重组腺相关病毒(rAAV)基因治疗对Duchenne型肌营养不良症(DMD)动物模型有着前所未有的有益效果,而需要在体内注入大量的载体来改善表型却明显地增加了生物安全问题。而重组腺相关病毒载体通常表现出良好的安全性,在营养缺乏的肌肉里观察到的特定的病理表型,可能促进了免疫毒性/遗传毒性效应。通过降低有效剂量增加DMD肌肉的rAAV的治疗指数可能是保证有效的临床应用的关键手段。这需要全面的了解总是在非病变组织或体外被研究的重组腺相关病毒转导的过程。在这篇综述中,我们专注于注射后rAAV的分子命运,以及在DMD的情况下如何影响到转导的各个阶段。
关键词: 肌肉,杜氏肌肉营养不良症,腺相关病毒,基因治疗,制约因素,在体内。
Current Gene Therapy
Title:Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles
Volume: 16 Issue: 3
Author(s): Jean-Baptiste Dupont
Affiliation:
关键词: 肌肉,杜氏肌肉营养不良症,腺相关病毒,基因治疗,制约因素,在体内。
摘要: Despite the unprecedented beneficial effects of rAAV gene therapy in animal models of Duchenne muscular dystrophy (DMD), the need to inject large amounts of vector in vivo to improve phenotype raises obvious biosafety concerns. While rAAV vectors generally exhibit a good safety profile, specific pathological phenotypes such as those observed in dystrophin-deficient muscles may promote immunotoxic/genotoxic effects. Increasing the therapeutic index of rAAV in DMD muscles by reducing the effective dose could be a pivotal means of ensuring efficient clinical translation. This requires a comprehensive understanding of the rAAV transduction process, which is almost always studied in non-pathological tissues or in vitro. In this review, we focus on the molecular fate of rAAV after injection, and how the individual stages of transduction could be affected in the context of DMD.
Export Options
About this article
Cite this article as:
Jean-Baptiste Dupont , Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles, Current Gene Therapy 2016; 16 (3) . https://dx.doi.org/10.2174/1566523216666160428104325
DOI https://dx.doi.org/10.2174/1566523216666160428104325 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials New Approach to Immunotherapy Against Organ-specific Autoimmune Diseases with T Cell Receptor and Chemokine Receptor DNA Vaccines
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Renin Angiotensin System as a Regulator of Cell Volume. Implications to Myocardial Ischemia
Current Cardiology Reviews Atrial Fibrillation: Epidemiology and Peculiarities in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets A Comprehensive Literature Search: Drugs as Possible Triggers of Takotsubo Cardiomyopathy
Current Clinical Pharmacology Blockade of Renin Angiotensin System Ameliorates the Cardiac Arrhythmias and Sympathetic Neural Remodeling in Hearts of Type 2 DM Rat Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Dopamine: The Forgotten Felon in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets Targeting Calcium and the Mitochondria in Prevention of Pathology in the Heart
Current Drug Targets Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine